| ACLARIS THERAPEUTICS DL 1 |
| USA |
| Gesundheit |
| US00461U1051 / A1412H |
| 8AT (Frankfurt) / ACRS (NASDAQ) |
| FRA:8AT, ETR:8AT, 8AT:GR, NASDAQ:ACRS |
| - |
| https://www.aclaristx.com.. |
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small- and large-molecule therapies for immuno-inflammatory diseases. The company centers its work on conditions with significant unm..
>Volltext.. |
| 564.1 Mio. EUR |
| 464.43 Mio. EUR |
| 5.81 Mio. EUR |
| -81.65 Mio. EUR |
| -72.25 Mio. EUR |
| -0.54 EUR |
| 1.55 Mio. EUR |
| 18.5 Mio. EUR |
| -68.23 Mio. EUR |
| 4.72 |
| -57.88% |
| 41.78% |
| - |
| - |
| - |
| - |
| ACLARIS |
| 16.11.26 |
|
||||
|